Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It remains unclear if the long-term response is associated with the characteristics of CAR T cells in infusion products, hindering the identification of biomarkers to predict therapeutic outcomes. Here, we present 101,326 single-cell transcriptomes and surface protein landscape from the infusion products of 12 ALL patients. We observed substantial heterogeneity in the antigen-specific activation states, among which a deficiency of T helper 2 function was associated with CD19-positive relapse compared with durable responders (remission, >54 months). Proteomic data revealed that the frequency of early memory T cells, rather than activation or coinhibitory signatures, could distinguish the relapse. These findings were corroborated by independent functional profiling of 49 patients, and an integrative model was developed to predict the response. Our data unveil the molecular mechanisms that may inform strategies to boost specific T cell function to maintain long-term remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis led to discovery of TH2 cell pathways and related genes as potential targets for maintaining 5-year remission following CAR T cell immunotherapy.”
From The technological landscape and applications of single-cell multi-omics (2023) · cites this paper as [166]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lack of TH2 functionality might be the cause of relapse in CAR-T treatment.”
From Single-cell sequencing to multi-omics: technologies and applications (2024) · cites this paper as [209]
In the citing paper
“Single-cell multi-omics has also been applied to assess chimeric antigen receptor (CAR) T cell therapy in acute lymphoblastic leukaemia, combining transcriptomics and proteomics data to determine the molecular basis of phenotypic differences between complete remission, non-responsive and relapsed individuals166.”
From The technological landscape and applications of single-cell multi-omics (2023) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · cited 3×
“All differential expression analyses were performed using Seurat v3 (48).”
MethodInfluentialUMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets.
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A. R., Kamitaki, N., Martersteck, E. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.002 · Cited by 7,110
UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction
McInnes, L., Healy, J., & Melville, J. (2018) · arXiv · doi:10.48550/arxiv.1802.03426 · Cited by 7,101 · cited 1×
“We used 20 canonical correlation analysis (CCA) dimensions and the default number of anchor neighbors and reduced the integrated mRNA data to two dimensions using UMAP for visualization (46).”
MethodScenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationCausal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Research works printed but not linked: 1
- S. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann, J. P. McGuirk, U. Jaeger, S. Jaglowski, C. Andreadis, J. R. Westin, I. Fleury, V. Bachanova, S. R. Foley, P. J. Ho, S. Mielke, J. M. Magenau, H. Holte, K. Van Besien, M. J. Kersten, T. Teshima, K. Tobinai, P. Corradini, O. Anak, L. B. Pacaud, C. del Corral, D. Pharma, R. Awasthi, F. Tai, G. Salles, R. T. Maziarz, Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
Cited by
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
The technological landscape and applications of single-cell multi-omics
Baysoy, A., Bai, Z., Satija, R., & Fan, R. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00615-w · Cited by 1,037
Self-citationCAR-T cell manufacturing: Major process parameters and next-generation strategies
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 303
FOXO1 is a master regulator of memory programming in CAR T cells
Doan, A. E., Mueller, K. P., Chen, A. Y., Rouin, G. T., Chen, Y., Daniel, B., Lattin, J., Markovska, M., Mozarsky, B., Arias-Umana, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07300-8 · Cited by 223
Self-citationSingle-cell sequencing to multi-omics: technologies and applications
Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., & Yang, R. (2024) · Biomarker Research · doi:10.1186/s40364-024-00643-4 · Cited by 222
“…mechanisms of resistance to CAR-T therapy in acute lymphoblastic leukemia (ALL), Bai et al. integrated scRNA-seq and CITE-seq to compare responders and CD19-positive relapse patients, during which they confirmed lack of T H 2 functionality might be the cause of relapse in CAR-T treatment [209].”
MethodSelf-citationExhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity
Yan, C., Zheng, L., Jiang, S., Yang, H., Guo, J., Jiang, L.-Y., Li, T., Zhang, H., Bai, Y., Lou, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.016 · Cited by 221
Multidimensional control of therapeutic human cell function with synthetic gene circuits
Li, H.-S., Israni, D. V., Gagnon, K. A., Gan, K. A., Raymond, M. H., Sander, J. D., Roybal, K. T., Joung, J. K., Wong, W. W., & Khalil, A. S. (2022) · Science · doi:10.1126/science.ade0156 · Cited by 172
Potential solutions for manufacture of CAR T cells in cancer immunotherapy
Blache, U., Popp, G., Dünkel, A., Koehl, U., & Fricke, S. (2022) · Nature Communications · doi:10.1038/s41467-022-32866-0 · Cited by 140
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
Feng, B., Bai, Z., Zhou, X., Zhao, Y., Xie, Y., Huang, X., Liu, Y., Enbar, T., Li, R., Wang, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07962-4 · Cited by 148
“…CAR-T cells with a 4-1BB costimulatory domain was found essential for ultra-long-term remission in patients with acute lymphoblastic leukaemia 4 , the IL-4 signalling pathway was recently reported to drive exhaustion of CAR-T cells that rely on a CD28 domain for costimulation 34 , suggesting…”
Self-citationLi, Y.-R., Zhou, Y., Yu, J., Kim, K. G., Li, M., Lee, D., Zhou, K., Chen, Y., Zhu, Y., Wang, Y.-C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02226-y · Cited by 139
“9a,b) 38–45 .”
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai, Z., Feng, B., McClory, S., de Oliveira, B. C., Diorio, C. J., Grégoire, C., Tao, B., Yang, L., Zhao, Z., Peng, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07762-w · Cited by 139
“Despite a limited sample size, our recent study identified a deficiency of T H 2 cells in CD19 + relapsed patients compared to durable responders 11 .”
Self-citationAdvancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 136
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao, Z., Chyra, Z., Kotulová, J., Celichowski, P., Mihályová, J., Charvátová, S., & Hájek, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01193-6 · Cited by 118
“Similar results were demonstrated by Bai et al. through cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) analysis, showing that frequencies of T SCM and T CM from CAR-T infusion products could distinguish relapse in patients [50].”
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 105
“When a correlation has been reported, its significance has been relatively weak ( p = 0.0464 [21], p = 0.0317 for central memory T cell (Tcm) [15], and p = 0.0327 [22]).”
BackgroundResultInfluentialEnhancing CAR-T cell functionality in a patient-specific manner
Zhang, D. K. Y., Adu‐Berchie, K., Iyer, S., Liu, Y., Cieri, N., Brockman, J. M., Neuberg, D. S., Wu, C. J., & Mooney, D. J. (2023) · Nature Communications · doi:10.1038/s41467-023-36126-7 · Cited by 103
Zhu, M., Han, Y., Gu, T., Wang, R. Y., Si, X., Kong, D., Zhao, P., Wang, X., Li, J., Zhai, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114065 · Cited by 99
Rejeski, K., Jain, M. D., & Smith, E. L. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.007 · Cited by 93
Wang, Y., Tong, C., Lu, Y., Wu, Z., Guo, Y., Liu, Y., Wei, J., Wang, C., Yang, Q., & Han, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01659-2 · Cited by 89
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 78
Deconvolution of clinical variance in CAR-T cell pharmacology and response
Kirouac, D. C., Zmurchok, C., Deyati, A., Sicherman, J., Bond, C., & Zandstra, P. W. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01687-x · Cited by 78
“…were developed using the same workflow excluding feature selection, with input features being either reported cell frequencies from Fraietta et al. 18 computed cell frequencies from Bai et al. CITE-seq data 34 or computed cell frequencies from ProjecTILs 33 annotation of Haradhvala et al. 32 data.”
BackgroundMethodInfluentialRade, M., Grieb, N., Weiss, R., Sia, J., Fischer, L., Born, P., Boldt, A., Fricke, S., Franz, P., Scolnick, J. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00763-8 · Cited by 78
“Single-cell RNA sequencing (scRNA-seq) has been successfully used to study cellular dynamics associated with response to CD19-directed CAR T cell therapy in large B cell lymphoma and acute lymphoblastic leukemia 10–12 .”
Li, Y.-R., Fang, Y., Niu, S., Zhu, Y., Chen, Y., Lyu, Z., Zhu, E., Tian, Y., Huang, J., Rezek, V. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56270-6 · Cited by 69
“10b and 11) 44,84 – 86 .”
Li, Y.-R., Li, Z., Zhu, Y., Li, M., Chen, Y., Lee, D. P. H., Ochoa, C. J., Singh, T., DiBernardo, G., Guo, W., et al. (2025) · Med · doi:10.1016/j.medj.2025.100804 · Cited by 70
Sabit, H., Arneth, B. M., Pawlik, T. M., Abdel-Ghany, S. E., Ghazy, A., Abdelazeem, R. M., Alqosaibi, A. I., Al-Dhuayan, I. S., Almulhim, J., Alrabiah, N. A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18010075 · Cited by 70
“The analysis highlighted TH2 cell pathways and associated genes as potential targets for sustaining long-term remission, particularly over five years, following CAR T cell immunotherapy [191].”
A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells
Sin, W., Jagannathan, N. S., Teo, D. B. L., Kairi, F., Fong, S. Y., Tan, J. H. L., Sandikin, D., Cheung, K.-W., Luah, Y. H., Wu, X., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01219-1 · Cited by 64
“…and neurotoxicity-or cytokine release syndrome-associated cytokines (GM-CSF, IFN-γ and TNF-ɑ ) upon encountering tumour cells, while microbioreactor CAR T cells secreted higher levels of type 2 cytokines (IL-4, IL-5 and IL-13), which have been associated with long-term remission 65 .”
Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies
Liu, Z., Li, Y.-R., Yang, Y., Zhu, Y., Yuan, W., Hoffman, T., Wu, Y., Zhu, E., Zarubova, J., Shen, J., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01272-w · Cited by 63
Succinate preserves CD8+ T cell fitness to augment antitumor immunity
Ma, K., Cheng, H., Wang, L., Xiao, H., Liu, F., Yang, Y. T., Xiao, Z., Tang, K., Li, S., Wang, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.017 · Cited by 65
Self-citationDeciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Huang, S., Wang, X., Wang, Y., Wang, Y., Fang, C., Wang, Y., Chen, S., Chen, R., Lei, T., Zhang, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01783-1 · Cited by 62
Cadiñanos-Garai, A., Flugel, C., Cheung, A., Jiang, E., Vaissié, A., & Abou‐El‐Enein, M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.006 · Cited by 58
“11,12 15 For instance, CAR T cell products enriched in memory-like T cells tend to persist longer and mediate superior antitumor responses, 15–17 while an abundance of exhausted T cells correlates with poor persistence and early relapse.”
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
IL-4 drives exhaustion of CD8+ CART cells
Stewart, C. M., Siegler, E. L., Sakemura, R. L., Cox, M. J., Huynh, T., Kimball, B. L., Mai, L., Can, İ., Roman, C. M., Yun, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51978-3 · Cited by 53
Shumilov, E., Scholz, J. K., Seib, M., Mazzeo, P., Wurm‐Kuczera, R., Vučinić, V., Holtick, U., Boyadzhiev, H., Melchardt, T., Hölscher, A. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015719 · Cited by 52
Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches
Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 56
“…Zhejiang Univ-Sci B (Biomed & Biotechnol) 2022 23(10):793-811 | indexing of transcriptomes and epitopes by sequenc‐ ing (CITE-seq), a deficiency of T helper 2 function was predictable and associated with CD19-positive relapse in CD19 CAR-T cell products from 12 R/R ALL patients (Bai et al., 2022).”
BackgroundPotency assays and biomarkers for cell-based advanced therapy medicinal products
Capelli, C., Cuofano, C., Pavoni, C., Frigerio, S., Lisini, D., Nava, S., Quaroni, M., Colombo, V., Galli, F., Bezukladova, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186224 · Cited by 60
Microtechnologies for single-cell and spatial multi-omics
Deng, Y., Bai, Z., & Fan, R. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00084-y · Cited by 46
Self-citationSchubert, M., Schmitt, A., Hückelhoven‐Krauss, A., Neuber, B., Kunz, A. B., Waldhoff, P., Vonficht, D., Yousefian, S., Jopp‐Saile, L., Wang, L., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01470-0 · Cited by 46
“, central memory or naïve CARTs, mediate better expansion, persistence and antitumor activity [59, 60], T cell exhaustion is associated with inferior response [61, 62].”
BackgroundT cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response
Hickey, J. W., Haist, M., Horowitz, N. B., Caraccio, C., Tan, Y., Rech, A. J., Baertsch, M., Rovira‐Clavé, X., Zhu, B., Vazquez, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113494 · Cited by 42
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
Kirouac, D. C., Zmurchok, C., & Morris, D. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00355-3 · Cited by 45
Rezvan, A., Romain, G., Fathi, M., Heeke, D., Martinez-Paniagua, M. A., An, X., Bandey, I. N., Montalvo, M. J., Adolacion, J. R. T., Saeedi, A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00768-3 · Cited by 39
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D. P., Hosszu, K., Cancio, M., Jakubowski, A. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015157 · Cited by 41
“58,60 Comparison of apheresis and EOP CAR T-cell products has identi fi ed dysfunctional/exhausted signatures that associate with decreased patient responses.”
Cheloni, G., Karagkouni, D., Pita-Juárez, Y. H., Torres, D., Kanata, E., Liegel, J. J., Avigan, Z. M., Saldarriaga, I., Chedid, G., Rallis, K. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59904-x · Cited by 39
Ma, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 40
“…previous scRNA-seq studies that identified T H 2 signalling deficiency as an indicator of antigen-positive leukaemia relapse post CAR T cell therapy 51,52 , clinical observations that showed that 4-1BBζ-CAR persisted longer than CD28ζ-CAR 53 , and our analysis in immunocompromised and…”
Chen, Y., Xin, Q., Qiu, J., Zhu, M., Li, Z., Qiu, J., Tu, J., & Li, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00725-5 · Cited by 39
“The limited durability of therapeutic effects remains a major challenge in adoptive CAR-T cell therapy across multiple diseases and is considered a primary cause of antigen-positive relapse [97].”
Jung, I.-Y., Bartoszek, R. L., Rech, A. J., Collins, S. M., Ooi, S., Williams, E. F., Hopkins, C. R., Narayan, V., Haas, N. B., Frey, N. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1175 · Cited by 39
Wang, Z., & Kelley, S. O. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01315-2 · Cited by 40
“Some evidence suggests that polyfunctional T cells, which can secrete multiple cytokines simultaneously, are associated with better clinical outcomes 123–125 .”
Four challenges to CAR T cells breaking the glass ceiling
Bailey, S. R., Berger, T. R., Graham, C., Larson, R. C., & Maus, M. V. (2022) · European Journal of Immunology · doi:10.1002/eji.202250039 · Cited by 35
Cheng, K., Feng, X., Chai, Z., Wang, Z., Liu, Z., Yan, Z., Wang, Y., & Zhang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044197 · Cited by 33
“However, nearly half of the patients experience tumor recurrence after anti-CD19 CAR T cells treatment [3], and CAR T cells are much less successful in the treatment of solid tumors [4].”
BackgroundArunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 30
Self-citationGiorgioni, L., Ambrosone, A., Cometa, M. F., Salvati, A. L., Nisticò, R., & Magrelli, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910365 · Cited by 29
“Although the microbioreactor still requires manual handling and biosafety cabinet (BSC) use, future iterations could operate with smaller footprints in noncleanroom environments [116].”
BackgroundGong, Y., Fei, P., Zhang, Y., Xu, Y., & Wei, J. (2025) · Advanced Science · doi:10.1002/advs.202501095 · Cited by 30
CAR T cell persistence in cancer
Mueller, K. P., Grenier, J. M., & Weber, E. W. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.014 · Cited by 28
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Military Medical Research · doi:10.1186/s40779-023-00486-4 · Cited by 27
Charitidis, F. T., Adabi, E., Ho, N., Braun, A., Tierney, C., Strasser, L., Thalheimer, F. B., Childs, L. H., Bones, J., Clarke, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202302992 · Cited by 27
Kuilman, T., Schrikkema, D. S., Gadiot, J., Gomez, R., Bies, L., Walker, J., Spaapen, R. M., Kok, H., Houg, D., Viyacheva, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55420-6 · Cited by 27
Castellanos-Rueda, R., Wang, K.-L. K., Forster, J. L., Driessen, A., Frank, J. A., Martínez, M. R., & Reddy, S. T. (2025) · Science Advances · doi:10.1126/sciadv.adp4008 · Cited by 29
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
Gross, G., Alkadieri, S., Meir, A., Itzhaki, O., Aharony-Tevet, Y., Yosef, S. B., Zenab, A., Shbiro, L., Toren, A., Yardeni, T., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02257-z · Cited by 24
Dreyzin, A., Shao, L., Cai, Y., Han, K. L., Procházková, M., Gertz, M., Yates, B., Shi, R., Martin, K., Taylor, N. N., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.019 · Cited by 24
Expanding the cytokine receptor alphabet reprograms T cells into diverse states
Zhao, Y., Ogishi, M., Pal, A., Su, L., Tao, P., Jiang, H., Rodriguez, G. E., Chen, X. T., Sun, Q., Rysavy, L. W., et al. (2025) · Nature · doi:10.1038/s41586-025-09393-1 · Cited by 21
“Recent studies link a high proportion of type 2 cells in CAR T therapy to durable remissions 31,40 .”
Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease
Hu, X., Beauchesne, P. R., Wang, C., Wong, A. W., Deuse, T., & Schrepfer, S. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.009 · Cited by 22
Wang, C., Wang, C., Liu, H., Zhao, S., Qiu, J., Li, P., Liu, Z., Sun, M., Shao, X., Wang, Y., et al. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230030 · Cited by 22
Oliver‐Caldés, A., Español‐Rego, M., Zabaleta, A., González‐Calle, V., Velázquez, S. N., Inogés, S., de Cerio, A. L.-D., Cabañas, V., López‐Muñoz, N., Rodríguez‐Otero, P., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3759 · Cited by 21
You, J., Yang, X., Zhao, J., Chen, H., Tang, Y., Ouyang, D., Liu, Y., Wang, Y., Xie, S., Chen, Y., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.110406 · Cited by 23
“However, relapse in patients has been reported in clinical trial[2, 3].”
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Chen, X., Chen, L. C., Khericha, M., Meng, X., Salvestrini, E., Shafer, A., Iyer, N., Alag, A. S., Ding, Y., Nicolaou, D. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0504 · Cited by 20
Wang, S., Scurti, G. M., Dalheim, A. V., Quinn, S., Stiff, P. J., & Nishimura, M. I. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010607 · Cited by 22
“3,4,10,11 12-15 Although our in vivo experiments are consistent with successful engraftment of CD19-speci fi c CAR T cells generated after IL-7 culture (Figure 6A), molecular studies are needed to con fi rm the persistence of transduced cells.”
BackgroundGonzález‐Martínez, B., Galán‐Gómez, V., Navarro‐Zapata, A., Mirones, I., Cobo, M., Pernas, A., Vallejo, S., Sánchez‐Zapardiel, E., León‐Triana, O., Echecopar, C., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105872 · Cited by 20
“Another patient, P3 (CR/MRD + at day +28) had a lower ratio; however, this was a patient with CD19 − /CD22 + blasts and treated with frozen product, which could have influenced the outcome.”
Multiplexed engineering and precision gene editing in cellular immunotherapy
Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 20
Capello, M., Sette, A., Plantinga, T. S., Thalhauser, C. J., Spires, V. M., Nuermberger, K., Blum, J. M., Higgs, B. W., Castro, P. G., Yu, C. Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011377 · Cited by 19
Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges
Piana, D., Iavarone, F., Paolis, E. D., Daniele, G., Parisella, F., Minucci, A., Greco, V., & Urbani, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168830 · Cited by 20
“Similarly, Bai et al. reported on the integration of scRNA-seq and CITE-seq analysis in CAR T-cells among pediatric patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL) [173].”
BackgroundDeGolier, K., Danis, E. P., D’Antonio, M. A., Cimons, J. M., Yarnell, M. C., Kedl, R. M., Kohler, M. E., Scott-Browne, J. P., & Fry, T. J. (2025) · Nature Immunology · doi:10.1038/s41590-024-02034-1 · Cited by 19
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
Rothemejer, F. H., Lauritsen, N. P., Søgaard, O. S., & Tolstrup, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253395 · Cited by 17
Haradhvala, N. J., & Maus, M. V. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0212 · Cited by 18
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 18
“Another study found that deficiency of Th2 cells in the infusion product was associated with resistance and poor CAR T-cell durability in pediatric patients with B-ALL [48].”
BackgroundNew insights on potency assays from recent advances and discoveries in CAR T-cell therapy
Shao, L., Zheng, Y., Somerville, R. P. T., Stroncek, D. F., & Jin, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1597888 · Cited by 17
Volta, L. G., & Gill, S. I. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100027 · Cited by 19
Zhao, K., Ren, C., Tang, D., Zhao, L., Chen, X., Wang, Y., & Xu, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101769 · Cited by 18
Fully closed cell sorter for immune cell therapy manufacturing
Matsumoto, M., Tashiro, S., Ito, T., Takahashi, K., Hashimoto, G., Kajihara, J., Miyahara, Y., Shiku, H., & Katsumoto, Y. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.012 · Cited by 18
Microfluidic device for the high-throughput and selective encapsulation of single target cells
Nakamura, M., Matsumoto, M., Ito, T., Hidaka, I., Tatsuta, H., & Katsumoto, Y. (2024) · Lab on a Chip · doi:10.1039/d4lc00037d · Cited by 16
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy
Conti, A. G., Evans, A. C., von Linde, T., Deguit, C. D. T., Whiteside, S. K., Wesolowski, A. J., Imianowski, C. J., Yamashita-Kanemaru, Y., Dahmani, L., Chapman, J., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02389-z · Cited by 15
“The presence of stem-like T cells within the pre-infusion product associates with improved antitumor responses in both preclinical and clinical settings 6–9 .”
Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy
Mamo, T., Dreyzin, A., Stroncek, D. F., & McKenna, D. H. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad179 · Cited by 15
Wenes, M., Lepez, A., Arinkin, V., Maundrell, K., Barábas, O., Simonetta, F., Dutoit, V., Romero, P. J., Martinou, J., & Migliorini, D. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200897 · Cited by 14
Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy
Foley, C., Swan, S. L., & Swartz, M. A. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300642 · Cited by 15
Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 14
“47 Similarly, loss of CAR T cells in ALL patients is associated with high expression of genes involved in interferon (IFN) response and Th1 differentiation in the apheresis product.”
Self-citationMavuluri, J., Dhungana, Y., Jones, L. L., Bhatara, S., Shi, H., Yang, X., Lim, S.-E., Reyes, N., Chi, H., Yu, J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0841 · Cited by 13
“Despite the remarkable success of CAR T-cell therapy in the treatment of CD19 + hematologic tumors (56), 30% to 50% of patients remain unresponsive or relapse within a year (57).”
Gordon, K. S., Perez, C. R., Garmilla, A., Lam, M. S. Y., Aw, J., Datta, A., Lauffenburger, D. A., Pavesi, A., & Birnbaum, M. E. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009574 · Cited by 11
“Reads were aligned to the Genome Reference Consortium Human Build 38 (GRCh38), and a cell-gene matrix was generated from the aligned reads using the CellRanger software (10x Genomics; V.7.0.1).”
InfluentialNaik, S., Aplenc, R., Baumeister, S. H. C., Becilli, M., Bhagwat, A. S., Bonifant, C. L., Budde, L. E., Chien, C. D., Curran, K. J., Daniyan, A. F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017011 · Cited by 11
“51,52 Description of the cell source must include if the product is autologous or allogeneic (tier 1).”
Proteasome-guided haem signalling axis contributes to T cell exhaustion
Xu, Y., Shangguan, Y., Chuang, Y., Chang, T.-H., Liu, W., Peng, J.-J., Garnica, J., Xie, L., Hsueh, P., Lin, M.-C., et al. (2026) · Nature · doi:10.1038/s41586-026-10250-y · Cited by 13
“…available scRNA-seq datasets of pre-infusion CD19 CAR-T from 94 patients with B-ALL and found that patients with long-term complete response had lower proteasome activity compared with patients with late relapse (complete response > 1.5 years) or patients with rapid relapse/non-response 41,42 (Fig.”
InfluentialSelf-citationChimeric antigen receptor therapies: Development, design, and implementation
Lee, M. J., Cichocki, F. M., & Miller, J. S. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.04.005 · Cited by 10
Alencar, G. F., Mohamed, A. O., Burnett, M. G., Jean, S. C. S., Nelson, A. R., Su, Y., Voillet, V., Bates, B. M., Suarez, M. L. R., Ruskin, S. L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2419888122 · Cited by 10
“Preinfusion cell product heterogeneity with similar numbers of distinct cell clusters have been reported for CAR-T cells (42–44).”
Tseng, H., Dholaria, B., Cranert, S. A., Richter, M., Marquez, K., Cho, B. S., Bacong, A., McArthur, K., Eskew, J. D., McCaigue, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65267-0 · Cited by 10
Zaninelli, S., Meli, C., Borleri, G., Quaroni, M., Pavoni, C., Gaipa, G., Biondi, A., Introna, M., Golay, J., Rambaldi, A., et al. (2023) · Cytometry Part A · doi:10.1002/cyto.a.24796 · Cited by 11
Barboy, O., Katzenelenbogen, Y., Shalita, R., & Amit, I. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0010 · Cited by 10
Enhancing the potency of CAR-T cells against solid tumors through transcription factor engineering
Chen, R., Chen, L., Tang, Y. R., Xiaolin, S., Wang, Y., Tang, P., Shentu, X., & Sun, J. (2025) · JCI Insight · doi:10.1172/jci.insight.193048 · Cited by 9
Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
Reinhardt, B., Lee, P. C., & Sasine, J. P. (2023) · Cells · doi:10.3390/cells12040531 · Cited by 9
Mapping T cell dynamics to molecular profiles through behavior-guided transcriptomics
Wezenaar, A. K. L., Pandey, U., Keramati, F., Hernandez-Roca, M., Brázda, P., Román, M. B., Cleven, A., Karaiskaki, F., Aarts‐Riemens, T., de Blank, S., et al. (2025) · Nature Protocols · doi:10.1038/s41596-024-01126-4 · Cited by 9
Applications of single‐cell omics for chimeric antigen receptor T cell therapy
Ghaffari, S., Saleh, M., Akbari, B., Ramezani, F. M., & Mirzaei, H. R. (2023) · Immunology · doi:10.1111/imm.13720 · Cited by 10
“…memory (T CM ) or stem cell memory (T SCM ) CAR T cells (CD62L + CCR7 + CD45RO + ), rather than activation spectra (CD69, CD38 and HLA-DR expression) or inhibitory signatures (PD-1, CTLA-4, LAG-3 and TIGIT expression), in the pre-infusion product correlates with CD19 positive B-ALL relapse [110].”
BackgroundResultGrzywa, T. M., Neeser, A., Ramasubramanian, R., Romanov, A. M., Tannir, R., Mehta, N. K., Cossette, B. J., Morgan, D. M., Goncalves, B., Sukaj, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01470-0 · Cited by 8
“Robust CAR-T cell engraftment and expansion in vivo is a prerequisite for anti-tumour efficacy 4 , a feature that is affected by several characteristics of the CAR-T cell product such as T cell quality 5 , CAR design 3,4,6 and the proportion of early memory T cells in the product 7 .”
Self-citationKe, Y., & Zhou, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1656108 · Cited by 9
Mapping clinical CAR-T cells: insights from scRNA-seq
Meehl, M. M., Ward, M. B., & Krenciute, G. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.006 · Cited by 8
Molina, J. C., Li, Y., Otto, W. R., Miller, T. P., Getz, K., McCoubrey, C., Ramos, M., Krause, E. M., Cao, L., Gramatges, M. M., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30062 · Cited by 7
Self-citationXu, Y. C., Wu, K.-C., Jiang, W., Hou, Y., Cheow, L. F., Lee, V. H.-F., & Chen, C.-H. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02562 · Cited by 7
Metadata
- Authors
- Bai, Z., Woodhouse, S., Zhao, Z., Arya, R., Govek, K., Kim, D., Lundh, S., Baysoy, A., Sun, H., Deng, Y., Xiao, Y., Barrett, D. M., Myers, R. M., Grupp, S. A., June, C. H., Fan, R., Camara, P. G., & Melenhorst, J. J.
- Affiliations
- Yale University (US)
- University of Pennsylvania (US)
- Cleveland Clinic (US)
- Children's Hospital of Philadelphia (US)
- Parker Institute for Cancer Immunotherapy (US)
- Yale Cancer Center (US)
- Department of Genetics and Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Corresponding author
- Bai, Zhiliang
- Woodhouse, Steven
- Fan, Rong
- Melenhorst, J. Joseph
- ORCID
- Venue
- Science Advances
- Published
- 2022-06-10
- Volume
- 8
- Issue
- 23
- Pages
- eabj2820-eabj2820
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC9177075
- OpenAlex
- W4281666488
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 36 · 2023: 36 · 2022: 13
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Yale University
- Entertainment Industry Foundation
- Li Ka Shing Foundation
- Society for Immunotherapy of Cancer
- Stand Up To Cancer
- National Cancer Institute (U01CA232361)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- acute lymphoblastic leukemia, CAR T-cell therapy, CD19, relapse, single-cell transcriptomics, T cell heterogeneity, co-inhibitory receptors, response prediction, biomarkers, T cell activation
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Recurrence, Immunotherapy, Adoptive, Antigens, CD19, Proteomics, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.